Related Experiment Video
Updated: Jun 25, 2025
05:44
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
Published on: November 5, 2020
4.3K
Elevation of the tumor marker CA19-9 in a pancreatic cancer survivor with benign prostatic hyperplasia: A clinical
Steve D Pendry1, Nimit Singhal2, Eu-Ling Neo3,4
1Flinders Health and Medical Research College of Medicine and Public Health Flinders University Bedford Park South Australia Australia.
Clinical Case Reports
|May 27, 2024
Summary
Serum carbohydrate antigen 19-9 (CA19-9) elevation in male pancreatic cancer survivors may indicate benign prostatic hyperplasia. This finding suggests considering prostate conditions when CA19-9 levels rise unexpectedly.
Area of Science:
- Oncology
- Urology
- Biomarker Research
Background:
- Serum carbohydrate antigen 19-9 (CA19-9) is a key biomarker for monitoring pancreatic ductal adenocarcinoma (PDAC) recurrence.
- Elevated CA19-9 levels in PDAC survivors typically warrant further investigation for cancer progression.
